Can Allergy Shots Make Eczema Worse? Understanding the Paradoxical Flare

Yes, temporarily — this is a real phenomenon occurring in approximately 10–15% of atopic dermatitis patients during the SCIT build-up phase (Werfel et al., JACI, 2006). The mechanism is the transient Th2 amplification that occurs before regulatory T cells establish immune tolerance. Atopic dermatitis is a Th2-driven disease, making patients vulnerable to this early immune stimulation. The critical context: worsening is typically temporary, peaks during weeks 4–12 of build-up, and resolves as maintenance phase begins and Treg-mediated tolerance develops. It does not indicate treatment failure. Long-term, SCIT often improves eczema by reducing the allergic immune burden driving skin inflammation.

Paradoxical eczema worsening during SCIT build-up typically peaks during weeks 4–12 of the build-up phase and resolves as patients transition to maintenance dosing, generally around months 3–6 of treatment. The resolution occurs as regulatory T cells develop sufficient numbers and function to suppress the Th2 pathway, and as IgG4 blocking antibody concentrations reach therapeutically meaningful levels. Patients who experience worsening should track their symptoms and communicate with their allergist about whether the timeline follows this expected pattern. Worsening that persists beyond 6 months, despite reaching maintenance dose, warrants re-evaluation — it may indicate that the extract formulation needs adjustment or that non-allergic factors are contributing to eczema severity.

SCIT should generally not be discontinued solely due to transient eczema worsening during the build-up phase, according to dermatological and allergist guidance. Stopping treatment at the point of temporary worsening means abandoning the treatment before it reaches the phase where it begins to provide benefit — which typically occurs after 3–6 months of consistent dosing. The appropriate response to eczema flares during build-up is management rather than discontinuation: intensify moisturizer application, use topical corticosteroids or calcineurin inhibitors for active flares, and communicate with your allergist about potentially slowing the dose escalation schedule. Your allergist and dermatologist should coordinate management. Dupilumab (anti-IL-4Rα biologic) can be used concurrently with SCIT and may prevent build-up phase eczema flares.

The patients most likely to experience paradoxical eczema worsening during SCIT build-up are those with the most active Th2-dominant immune baseline. Risk factors include: the atopic triad (concurrent atopic dermatitis, allergic rhinitis, and asthma), which indicates a strongly Th2-biased immune system; high baseline eczema severity (SCORAD above 40–50 before starting SCIT); polysensitization to multiple allergens, which means broader initial Th2 stimulation; and starting SCIT during peak allergen season, which combines environmental and injection-mediated allergen exposure. Patients with severe uncontrolled eczema (SCORAD above 50) may need to stabilize their skin condition with appropriate therapy before initiating SCIT, to reduce the severity of potential paradoxical worsening.

Yes — long-term SCIT can improve atopic dermatitis in patients with IgE-mediated allergen sensitization. A meta-analysis by Bae et al. published in Allergy (2013) found reduced SCORAD scores in atopic dermatitis patients who completed 3+ years of allergen immunotherapy. The mechanism is the sustained immune shift away from Th2-dominant inflammation: reduced IL-4, IL-13, and IgE over time decreases the cytokine burden driving skin barrier disruption and chronic eczema. The irony is that the same treatment that temporarily worsens eczema during build-up eventually improves it through long-term immune remodeling. Patients who persevere through the transient build-up flare are positioned to benefit from this long-term improvement.

A proactive management plan for eczema during SCIT build-up includes several evidence-based strategies. First, intensify moisturization: apply emollients (ceramide-containing creams or petroleum-based products) immediately after bathing while skin is damp, and reapply throughout the day. Second, have appropriate rescue therapy ready: your dermatologist should prescribe topical corticosteroids or topical calcineurin inhibitors (tacrolimus, pimecrolimus) for active flares. Third, communicate with your allergist: if flares are severe, they may slow the dose escalation schedule, accepting a longer build-up phase in exchange for less intense worsening. Fourth, consider advanced options: dupilumab (Dupixent) is approved for moderate-to-severe atopic dermatitis and can be used concurrently with SCIT, potentially preventing the Th2-mediated flare during build-up. Coordinate care between your allergist and dermatologist.